Reversible Cancer Therapeutics-related Cardiac Dysfunction Complicating Intra-cardiac Thrombi

Epirubicin-based chemotherapy carries a risk of inducing heart failure, although the frequency is rare. Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, has recently been widely used in patients with recurrent breast cancer as a first-line chemotherapeutic agent. Heart fa...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Internal Medicine 2020/09/01, Vol.59(17), pp.2155-2160
Hauptverfasser: Tsujinaga, Shingo, Iwano, Hiroyuki, Oshino, Tomohiro, Kadosaka, Takahide, Mizuguchi, Yoshifumi, Motoi, Ko, Chiba, Yasuyuki, Koya, Taro, Temma, Taro, Kamiya, Kiwamu, Fukushima, Arata, Koizumi, Takuya, Sato, Tomoya, Takenaka, Sakae, Tada, Atsushi, Ishizaka, Suguru, Sarashina, Miwa, Omote, Kazunori, Kamada, Rui, Konishi, Takao, Sato, Takuma, Nagai, Toshiyuki, Yamashita, Hiroko, Anzai, Toshihisa
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Epirubicin-based chemotherapy carries a risk of inducing heart failure, although the frequency is rare. Bevacizumab, an anti-vascular endothelial growth factor monoclonal antibody, has recently been widely used in patients with recurrent breast cancer as a first-line chemotherapeutic agent. Heart failure or arterial thromboembolism has been reported as a rare cardiovascular complication of bevacizumab. We herein report a breast cancer patient with reversible cancer therapeutics-related cardiac dysfunction associated with bevacizumab and epirubicin complicating intracardiac thrombi in the left atrium and left ventricle. This case underscores the importance of tailored medical planning according to the individual status in patients receiving anti-cancer therapies.
ISSN:0918-2918
1349-7235
DOI:10.2169/internalmedicine.4792-20